Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia Lei M, Liu L, Wang Z, Wu
Marine Drugs | Free Full-Text | Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms | HTML
Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia | HTML
A: RFS and (B) OS of 130 patients given ARA-C at standard dose (SDAC,... | Download Scientific Diagram
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. - Abstract - Europe PMC
PDF) Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells | Larry Matherly - Academia.edu
Frontiers | Increased HDAC Activity and c-MYC Expression Mediate Acquired Resistance to WEE1 Inhibition in Acute Leukemia
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Histone Deacetylase Inhibitors in Multiple Myeloma | SpringerLink
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaem
HDAC - high-dose ara-C
3942-Consolidation HiDAC (cytarabine) 1,2,3 | eviQ
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia | Haematologica
Cytarabine - Wikipedia
A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine
A new pattern of cytosineâ•'arabinosideâ•'induced lung toxicity
The HDI model of HDAC inhibition in leukemic cells . HDI inhibits HDAC,... | Download Scientific Diagram
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
